Physician profile
Kathleen E Corey
NPI 1326174038
$81,211.67
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $11K · 2021: $18K · 2022: $5,804 · 2023: $4,627 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $1,312 · Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,095.00 |
| Travel and Lodging | $1,312.41 |
| Food and Beverage | $398.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $35,064.66 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $14,972.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,178.83 | 2025 | |
| Theratechnologies INC. | $5,500.00 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $4,600.00 | 2023 | |
| Novo Nordisk INC | $4,564.54 | 2019-2021 | |
| Astrazeneca Ab | $2,148.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.93 | 2023 | Abilify Asimtufii, Abilify Maintena |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Corey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.